Close

Warning

You are about to leave ethypharm.com

Regulations vary by country. The information provided on the website you wish to visit may not correspond to that of your country.

Click on CONTINUE if you wish to access the site of one of our subsidiaries.

Continue

Ethypharm – Beyond our medicines, lives

Beyond our medecines, lives

Ethypharm is a specialty pharmaceutical company with European roots, focused on specific Central Nervous System (CNS) diseases and conditions, and on adding value to medicines used in Critical Care situations.

  Discover Ethypharm at a glance
Ethypharm HomePage

A commitment to the patients we serve

Many of our products are indicated for sensitive situations in which patients either suffer from debilitating conditions such as chronic pain or addiction, or are in a critical state.
All around the world, Ethypharm employees are engaged daily to make the difference for patients’ lives by ensuring that people in need are able to receive the right treatment at the right time and with the right support.

Read more on our commitments

Adding value in CNS and Critical Care

Ethypharm is deeply engaged in the CNS and Critical Care areas, where our medicines treat patients today and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and opioid dependency, we are constantly screening opportunities in search for those which will respond to unmet needs in our 2 core therapeutic areas.

CNS at Ethypharm Critical Care at Ethypharm

A Group on a dynamic development journey

Ethypharm is a rapidly transforming company, with a clear strategy and significant growth ambition. Our teams are constantly looking for opportunities to develop our product portfolio, selectively enlarge our geographical coverage and enrich our development pipeline. We are extremely open to discussing potential partnerships. Get to know our R&D and business development (BD) teams and come discuss with us!

R&D at Ethypharm BD at Ethypharm

Ethypharm Join Us

Ethypharm's latest news

Ethypharm Digital Therapy announces the launch of its website

On December 17th, 2021 – Ethypharm Digital Therapy (EDT) announces a new step on its development path with the launch of its website.
This new window on digital therapies (DTx) will allow EDT to inform a wide audience about the health benefits of DTx.

Click here to discover the new website
NB: By clicking on this link, you will be redirected to an external website

 

 

Ethypharm is the first European pharmaceutical laboratory to be awarded the LUCIE 26000 label for its CSR commitment.

On December 16, 2021 – Ethypharm announces that it has obtained the LUCIE 26000 label and joins Europe’s leading committed and responsible community. A first for a pharmaceutical company. This certification initially concerns Ethypharm’s main European subsidiaries: United Kingdom, France and Germany.
This certification reflects Ethypharm’s commitment to a CSR approach that is fully integrated into its development and respects all its stakeholders.

Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website

Ethypharm is growing fast and is always looking to enrich its teams with new talented individuals. We encourage you to visit this site regularly and to follow Ethypharm on LinkedIn to read our latest updates and stay informed about our job opportunities.

Linked